Pharmacogenetic approach for cancer treatment-tailored medicine in practice

Yoshinori Hasegawa, Yuichi Ando, Maki Ando, Naozumi Hashimoto, Kazuyoshi Imaizumi, Kaoru Shimokata

研究成果: Conference contribution

18 被引用数 (Scopus)

抄録

This article focuses on pharmacogenetic associations between genetic polymorphism of uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity. Accumulating evidence provides support to the idea that determination of UGT1A1 polymorphisms before irinotecan treatment is clinically useful and important for predicting and avoiding related toxicities. On the basis of these backgrounds, the irinotecan label was updated in 2005 in the United States to provide pharmacogenetic information, and a dose reduction of irinotecan should be considered for patients known to be homozygous for the UGT1A1*28 allele when administered in combination with other agents or a single agent. The irinotecan/UGT1A1 issue and the development of molecular diagnostic testing are now to be translated into clinical practice.

本文言語English
ホスト出版物のタイトルIntegrated Molecular Medicine for Neuronal and Neoplastic Disorders
出版社Blackwell Publishing Inc.
ページ223-232
ページ数10
ISBN(印刷版)1573316555, 9781573316552
DOI
出版ステータスPublished - 11-2006
外部発表はい

出版物シリーズ

名前Annals of the New York Academy of Sciences
1086
ISSN(印刷版)0077-8923
ISSN(電子版)1749-6632

All Science Journal Classification (ASJC) codes

  • 神経科学(全般)
  • 生化学、遺伝学、分子生物学(全般)
  • 科学史および科学哲学

フィンガープリント

「Pharmacogenetic approach for cancer treatment-tailored medicine in practice」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル